Therefore, we speculated that dioscin could indirectly regulate and intervene in other 22 known RA targets by directly acting on the four targets, i.e., CCL5, CXCL10, CXCR2, and IL2, in treating RA. The gene discussed is IL2; the disease is rheumatoid arthritis.